Ancylostomiasis medical therapy

Revision as of 09:11, 19 August 2021 by Kalpana (talk | contribs)
Jump to navigation Jump to search

Ancylostomiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ancylostomiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

Endoscopy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ancylostomiasis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ancylostomiasis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ancylostomiasis medical therapy

CDC on Ancylostomiasis medical therapy

Ancylostomiasis medical therapy in the news

Blogs on Ancylostomiasis medical therapy

Directions to Hospitals Treating Ancylostomiasis

Risk calculators and risk factors for Ancylostomiasis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

Anti-helminthic therapies are recommended among patients with ancylostomiasis.[1]

  • For stable uncomplicated cases
    • Adult
      • Preferred regimen: Albendazole 400 mg PO single dose
      • Alternative regimen: Mebendazole 100 mg PO q12h for 3 days
      • Alternative regimen: Pyrantel Pamoate 11mg/kg PO q24h for 3 days (maximum, 1gm per dose)

References

  1. Loukas A, Hotez PJ, Diemert D, Yazdanbakhsh M, McCarthy JS, Correa-Oliveira R; et al. (2016). "Hookworm infection". Nat Rev Dis Primers. 2: 16088. doi:10.1038/nrdp.2016.88. PMID 27929101.

Template:WH Template:WS